Tbo-filgrastim Subcutaneous and Zevalin Y-90

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using ibritumomab tiuxetan during or too soon after completion of a course of tbo-filgrastim treatment may alter the effects of either medication. Tbo-filgrastim should generally not be given within 2 weeks before or 2 weeks after treatment with ibritumomab tiuxetan. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

ADJUST DOSING INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with ibritumomab have not been established. Patients in clinical studies were prohibited from receiving growth factor treatment for 2 weeks prior to the ibritumomab therapeutic regimen and for 2 weeks following completion of the regimen.

MANAGEMENT: Until further data are available, it may be appropriate to avoid using hematopoietic growth factors within 2 weeks before or 2 weeks after the ibritumomab regimen.

Tbo-filgrastim Subcutaneous

Generic Name: tbo-filgrastim

Brand name: Granix

Synonyms: Tbo-filgrastim

What is Tbo-filgrastim Subcutaneous?

Zevalin Y-90

Generic Name: ibritumomab

Brand name: Y-90 Zevalin, In-111 Zevalin

Synonyms: Y-90 Zevalin

What is Zevalin Y-90?